https://www.iconovo.se/wp-content/uploads/2022/06/7-1.jpg
900
1600
Roger Lassing
https://www.iconovo.se/wp-content/uploads/2026/01/Breathtaking-innovation_Iconovo-300x92-2026.png
Roger Lassing2024-11-04 08:39:212024-11-04 08:39:21Iconovo’s partner Amneal has taken the next important step in the clinical development of ICOres budesonide/formoterolLatest news
https://www.iconovo.se/wp-content/uploads/2022/06/7-1.jpg
900
1600
Roger Lassing
https://www.iconovo.se/wp-content/uploads/2026/01/Breathtaking-innovation_Iconovo-300x92-2026.png
Roger Lassing2024-11-04 08:39:212024-11-04 08:39:21Iconovo’s partner Amneal has taken the next important step in the clinical development of ICOres budesonide/formoterol
https://www.iconovo.se/wp-content/uploads/2023/12/Iconovo-LinkedIn-post-1200x627-231127_16.jpg
627
1200
Roger Lassing
https://www.iconovo.se/wp-content/uploads/2026/01/Breathtaking-innovation_Iconovo-300x92-2026.png
Roger Lassing2024-09-20 13:16:292024-09-20 13:16:29Iconovo receives positive guidance from FDA regarding substitutability for ICOpre
https://www.iconovo.se/wp-content/uploads/2024/09/Iconovo-LinkedIn-post-1200x627-240904-pg2.jpg
1003
1920
Roger Lassing
https://www.iconovo.se/wp-content/uploads/2026/01/Breathtaking-innovation_Iconovo-300x92-2026.png
Roger Lassing2024-09-16 11:45:292024-09-16 11:45:29BIOSTOCK: The future of obesity treatment – Iconovo develops intranasal semaglutideFollow us on Linkedin
